• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌细胞周期错乱:异质性、可塑性和治疗。

Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy.

机构信息

Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.

Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.

出版信息

Trends Cancer. 2022 Sep;8(9):711-725. doi: 10.1016/j.trecan.2022.04.006. Epub 2022 May 20.

DOI:10.1016/j.trecan.2022.04.006
PMID:35599231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9388619/
Abstract

The mammalian cell cycle has been extensively studied regarding cancer etiology, progression, and therapeutic intervention. The canonical cell cycle framework is supported by a plethora of data pointing to a relatively simple linear pathway in which mitogenic signals are integrated in a stepwise fashion to allow progression through G1/S with coordinate actions of cyclin-dependent kinases (CDK)4/6 and CDK2 on the RB tumor suppressor. Recent work on adaptive mechanisms and intrinsic heterogeneous dependencies indicates that G1/S control of the cell cycle is a variable signaling pathway rather than an invariant engine that drives cell division. These alterations can limit the effectiveness of pharmaceutical agents but provide new avenues for therapeutic interventions. These findings support a dystopian view of the cell cycle in cancer where the canonical utopian cell cycle is often not observed. However, recognizing the extent of cell cycle heterogeneity likely creates new opportunities for precision therapeutic approaches specifically targeting these states.

摘要

哺乳动物细胞周期在癌症的病因、进展和治疗干预方面已经得到了广泛的研究。经典的细胞周期框架得到了大量数据的支持,这些数据表明,在这个框架中,有一个相对简单的线性途径,其中有丝分裂信号以逐步的方式整合,允许细胞通过 G1/S 期进行,同时细胞周期蛋白依赖性激酶(CDK)4/6 和 CDK2 对 RB 肿瘤抑制因子进行协调作用。最近关于适应性机制和内在异质依赖性的研究工作表明,G1/S 期对细胞周期的控制是一个可变的信号通路,而不是驱动细胞分裂的不变引擎。这些改变可能会限制药物制剂的有效性,但为治疗干预提供了新的途径。这些发现支持了癌症中细胞周期的反乌托邦观点,在这种观点中,经典的乌托邦细胞周期通常是观察不到的。然而,认识到细胞周期异质性的程度可能会为专门针对这些状态的精确治疗方法创造新的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/3049d87c8b40/nihms-1810625-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/e1ab9da4b516/nihms-1810625-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/112cc93b7fdd/nihms-1810625-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/32e4da97d65c/nihms-1810625-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/88d86cb893c0/nihms-1810625-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/3049d87c8b40/nihms-1810625-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/e1ab9da4b516/nihms-1810625-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/112cc93b7fdd/nihms-1810625-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/32e4da97d65c/nihms-1810625-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/88d86cb893c0/nihms-1810625-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b55/9388619/3049d87c8b40/nihms-1810625-f0005.jpg

相似文献

1
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy.癌细胞周期错乱:异质性、可塑性和治疗。
Trends Cancer. 2022 Sep;8(9):711-725. doi: 10.1016/j.trecan.2022.04.006. Epub 2022 May 20.
2
Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.p16(INK4a) 的诱导表达通过细胞周期蛋白 - 细胞周期蛋白依赖性激酶 - 抑制剂复合物的重新组合来抑制CDK4和CDK2相关激酶活性。
Mol Cell Biol. 1999 Mar;19(3):1981-9. doi: 10.1128/MCB.19.3.1981.
3
Formation of p27-CDK complexes during the human mitotic cell cycle.人类有丝分裂细胞周期中p27 - CDK复合物的形成。
Cell Growth Differ. 1996 Feb;7(2):135-46.
4
Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.终末红细胞分化过程中的细胞周期退出与p27(Kip1)的积累和cdk2激酶的失活有关。
Blood. 2000 Oct 15;96(8):2746-54.
5
Retinoic acid-mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells.维甲酸介导的G1期阻滞与人肺鳞状癌CH27细胞中p27(Kip1)的诱导及细胞周期蛋白依赖性激酶3的抑制有关。
Exp Cell Res. 2000 Aug 1;258(2):322-31. doi: 10.1006/excr.2000.4933.
6
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.Kip/Cip和Ink4细胞周期蛋白依赖性激酶抑制剂协同作用,以响应转化生长因子-β诱导细胞周期停滞。
Genes Dev. 1995 Aug 1;9(15):1831-45. doi: 10.1101/gad.9.15.1831.
7
Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1).转化生长因子β(1)通过阻止细胞周期蛋白D3-细胞周期蛋白依赖性激酶4与细胞核p27(kip1)的结合,选择性抑制原代甲状腺上皮细胞的环磷酸腺苷依赖性增殖。
Mol Biol Cell. 2000 Mar;11(3):1061-76. doi: 10.1091/mbc.11.3.1061.
8
Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus.卡波西肉瘤相关疱疹病毒编码的细胞周期蛋白对p27(Kip1)水平的调节
EMBO J. 1999 Feb 1;18(3):654-63. doi: 10.1093/emboj/18.3.654.
9
Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.通过调节CDK2活性,12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)对黑色素瘤细胞周期的抑制及在G1/S期转换的调控
Exp Cell Res. 1995 Nov;221(1):92-102. doi: 10.1006/excr.1995.1356.
10
Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation.细胞周期蛋白依赖性激酶3(cdk3)相关激酶活性的调控研究以及cdk3在细胞增殖和转化中的作用。
Oncogene. 1998 Oct 29;17(17):2259-69. doi: 10.1038/sj.onc.1202145.

引用本文的文献

1
Subtle alteration in transcriptional memory governs the lineage-level cell cycle duration heterogeneities of mammalian cells.转录记忆中的细微变化决定了哺乳动物细胞谱系水平的细胞周期持续时间异质性。
iScience. 2025 Jun 21;28(7):112981. doi: 10.1016/j.isci.2025.112981. eCollection 2025 Jul 18.
2
FBXO32 promotes gastric cancer progression by regulating NME1.FBXO32通过调节NME1促进胃癌进展。
Transl Cancer Res. 2025 Jun 30;14(6):3520-3531. doi: 10.21037/tcr-2024-2426. Epub 2025 Jun 27.
3
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer.

本文引用的文献

1
Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.功能基因组分析 CDK4 和 CDK6 基因在人类癌细胞系中的依赖性。
Cancer Res. 2022 Jun 6;82(11):2171-2184. doi: 10.1158/0008-5472.CAN-21-2428.
2
CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities.CDK/周期蛋白依赖性决定了极端的癌细胞周期异质性和附带脆弱性。
Cell Rep. 2022 Mar 1;38(9):110448. doi: 10.1016/j.celrep.2022.110448.
3
Active RB causes visible changes in nuclear organization.活性 RB 导致核组织发生可见变化。
基线细胞周期和免疫图谱表明转移性HR+/HER2-乳腺癌对CDK4/6抑制剂的反应。
NPJ Breast Cancer. 2025 Jun 12;11(1):54. doi: 10.1038/s41523-025-00767-2.
4
Current advances in cancer immunohistochemistry: a new perspective for the Ki-67 biomarker.癌症免疫组织化学的当前进展:Ki-67生物标志物的新视角
Ecancermedicalscience. 2025 Mar 5;19:1863. doi: 10.3332/ecancer.2025.1863. eCollection 2025.
5
Cellular senescence in age-related musculoskeletal diseases.与年龄相关的肌肉骨骼疾病中的细胞衰老
Front Med. 2025 May 2. doi: 10.1007/s11684-025-1125-7.
6
IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner.IGF2BP3通过以m6A依赖的方式增强CDK6的mRNA稳定性来促进膀胱癌的增殖和顺铂耐药性。
Int J Biol Sci. 2025 Feb 18;21(5):2048-2066. doi: 10.7150/ijbs.103522. eCollection 2025.
7
PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1/S Progression and Epithelial-Mesenchymal Transition.PRR11通过促进G1/S期进程和上皮-间质转化促进膀胱癌的生长和转移。
Cancer Med. 2025 Mar;14(5):e70749. doi: 10.1002/cam4.70749.
8
Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222.肿瘤抑制因子对选择性CDK2抑制剂BLU-222的条件性差异反应。
Cancer Res. 2025 Apr 3;85(7):1310-1326. doi: 10.1158/0008-5472.CAN-24-2244.
9
Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.对药理学CDK2抑制的离散易感性由癌细胞周期的异质性决定。
Nat Commun. 2025 Feb 9;16(1):1476. doi: 10.1038/s41467-025-56674-4.
10
Novel pharmacologic inhibition of lysine-specific demethylase 1 as a potential therapeutic for glioblastoma.赖氨酸特异性去甲基化酶1的新型药理学抑制作为胶质母细胞瘤的潜在治疗方法。
Cancer Gene Ther. 2024 Dec;31(12):1884-1894. doi: 10.1038/s41417-024-00847-8. Epub 2024 Nov 5.
J Cell Biol. 2022 Mar 7;221(3). doi: 10.1083/jcb.202102144. Epub 2022 Jan 12.
4
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.系统评价分子生物标志物预测转移性乳腺癌对 CDK4/6 抑制的耐药性。
JCO Precis Oncol. 2022 Jan;6:e2100002. doi: 10.1200/PO.21.00002.
5
Pharmacological CDK4/6 inhibition reveals a p53-dependent senescent state with restricted toxicity.药理 CDK4/6 抑制揭示了一种依赖 p53 的衰老状态,其毒性受限。
EMBO J. 2022 Mar 15;41(6):e108946. doi: 10.15252/embj.2021108946. Epub 2022 Jan 5.
6
Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability.细胞周期蛋白E/细胞周期蛋白依赖性激酶2:DNA复制、复制应激与基因组不稳定
Front Cell Dev Biol. 2021 Nov 24;9:774845. doi: 10.3389/fcell.2021.774845. eCollection 2021.
7
Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma.RB1 突变型骨肉瘤中对 PARP1、2 抑制的治疗易感性。
Nat Commun. 2021 Dec 3;12(1):7064. doi: 10.1038/s41467-021-27291-8.
8
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.复制应激生物标志物与卵巢癌中吉西他滨与吉西他滨联合 ATR 抑制剂治疗反应相关。
Nat Commun. 2021 Sep 22;12(1):5574. doi: 10.1038/s41467-021-25904-w.
9
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.INK4 肿瘤抑制蛋白介导对 CDK4/6 激酶抑制剂的耐药性。
Cancer Discov. 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20.
10
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.使用CDK2/4/6抑制剂扩大对肿瘤细胞周期的控制。
Cancer Cell. 2021 Oct 11;39(10):1404-1421.e11. doi: 10.1016/j.ccell.2021.08.009. Epub 2021 Sep 13.